Ulcavis (Bismuth tripotassium dicitrate)

Instructions for Ulcavis (Bismuth tripotassium dicitrate)

English product name
Ulcavis

Release Form
Shell-coated tablets

Composition Ulcavis

Active substance: bismuth tripotassium dicitrate 303.03 mg (equivalent to bismuth oxide 120 mg) Auxiliary substances: corn starch - 72.17 mg; Povidone K30 - 18 mg; potassium polycrylene - 23.8 mg; macrogol 6000 - 6 mg; magnesium stearate - 2 mg film shell: Opadry II transparent (polyvinyl alcohol - 4.505 mg, macrogol 4000 - 2.295 mg; talc - 1.7 mg) - 8.5 mg; titanium dioxide (E) 171) - 1.5 mg

Pharmacological effect Ulcavis
Antiulcerative, gastroprotective, antihelicobacter

Testimony Ulcavis

• Gastritis and duodenal ulcer in the exacerbation phase, 
• including those associated with Helicobacter pylori;
• chronic gastritis and gastroduodenitis in the exacerbation phase,
• including those associated with Helicobacter pylori;
• irritable bowel syndrome,
• mainly associated with diarrhoea symptoms;
• functional dyspepsia,
• not associated with organic gastrointestinal diseases

Method of use and doses Ulcavis

Inside, 30 minutes before the meal, with a little water. For adults and children over 12 years of age, Ulkavis is prescribed one table four times a day, 30 minutes before meals and two tables twice a day. For children aged eight to 12, Ulkavis is prescribed one tablet each. twice a day; for 4 to 8 years, eight mg/kg/day is prescribed, depending on the child's body weight, one tableau/day (one to two daily doses, respectively).

Description Ulcavis
Round slightly double-convex tablets, coated with a film shell of white or almost white, odorless or with a faint smell of ammonia, with a chamfer.

Fracture view: white rough mass

Storage Conditions
At a temperature not higher than 25 °C, in the original package.
Store in a place not accessible to children.

Best before date Bismuth tripotassium dicitrate
three years.
Do not use the drug after the expiry date.